ArticleNature communications2024
A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Advancing lung organoids toward clinical applications: a global perspective on research focus and future directions.Frontiers in medicine · 2025Pooled it
- Phase-Separated Nanoarchitecture of Adhesion-Cytoskeleton Force Coupling Reforms Nuclear Spatiotemporal Posture Conformation and Mechanotransduction of Osteosarcoma on Biofunctional Microarrays.Advanced healthcare materials · 2026Article
- Biofabrication for spatial control of multiscale biological crosstalk in tissue models.npj biomedical innovations · 2026Review
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
- Self-assembly of tumor-related vascularized colorectal tumoroid-on-a-chip for precision medicine drug testing.Cell reports. Medicine · 2026Article
- Patient-specific lung cancer tumoroids recapitulate the tumor microenvironments for functional evaluation of therapeutic responses and immune-stromal interactions.Journal of translational medicine · 2026Article
- Patient-derived three-dimensional lung tumor models to evaluate response to therapy.NPJ precision oncology · 2026Article
- Tumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readouts.Archives of pharmacal research · 2026Review
- Patient-Derived Lung Cancer Organoids for Precision Oncology: A Comprehensive Analysis.JTO clinical and research reports · 2026Article
- Beyond the chaos: How architecture structures tumour biology.The FEBS journal · 2026Review
- Tumor Organoid and Microenvironment Cocultures: Implications for Basic and Translational Cancer Research.MedComm · 2026Review
- Dynamic granular hydrogels to assess pancreatic cancer cell fate.Biomaterials science · 2026Article
- AI-integrated microfluidics for drug screening: From single cell to organ-on-a-chip.Acta pharmaceutica Sinica. B · 2026Review
- From organoid culture to manufacturing: technologies for reproducible and scalable organoid production.npj biomedical innovations · 2026Review
- Parabiosis, Assembloids, Organoids (PAO).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.Advanced healthcare materials · 2026Review
- Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support.Frontiers in oncology · 2026Review
- Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges.Drug design, development and therapy · 2026Review
- Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects.MedComm · 2026Review
- Hydrogel Microspheres for Biomedical Applications.Small science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer models play critical roles in basic cancer research and precision medicine. However, current in vitro cancer models are limited by their inability to mimic the three-dimensional architecture and heterogeneous tumor microenvironments (TME) of in vivo tumors. Here, we develop an innovative patient-specific lung cancer assembloid (LCA) model by using droplet microfluidic technology based on a microinjection strategy. This method enables precise manipulation of clinical microsamples and rapid generation of LCAs with good intra-batch consistency in size and cell composition by evenly encapsulating patient tumor-derived TME cells and lung cancer organoids inside microgels. LCAs recapitulate the inter- and intratumoral heterogeneity, TME cellular diversity, and genomic and transcriptomic landscape of their parental tumors. LCA model could reconstruct the functional heterogeneity of cancer-associated fibroblasts and reflect the influence of TME on drug responses compared to cancer organoids. Notably, LCAs accurately replicate the clinical outcomes of patients, suggesting the potential of the LCA model to predict personalized treatments. Collectively, our studies provide a valuable method for precisely fabricating cancer assembloids and a promising LCA model for cancer research and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.